Are There Histological Markers for Targeted Therapy?
Yes, certain histological markers are used to identify candidates for targeted therapies:
- HER2: Overexpression in gastric and colorectal cancers can be targeted with trastuzumab. - MSI (Microsatellite Instability): High MSI in colorectal cancer predicts responsiveness to immunotherapy. - KRAS: Mutations in colorectal cancer predict non-responsiveness to EGFR inhibitors.
